（编辑 王雪儿） 证券日报网讯 三鑫医疗8月13日发布公告，在公司回答调研者提问时表示，公司自主研发并作为国产品 牌首次获得审批注册的一次性使用血液透析器（湿膜，高通量/非高通量），作为普通透析器迭代升级 产品服务于广大透析患者，其以先进的透析膜湿化填充工艺和更加优异的生物相容性，减少了过敏反 应，提升了患者的透析体验和生存质量，该产品与PP、PC材质高通量、非高通量"干膜"透析器，共同 构成国产品牌血液透析器最齐全的产品群。公司正稳步推进湿膜透析器在各地区的市场准入和入院工 作，全力做好与医保的配合、与集采政策的衔接，通过差异化的竞争策略提升血液透析器的市场份额， 不断扩大湿膜透析器的临床应用。 ...

Core Viewpoint - The company, Kangtai Medical, has reported a significant decline in performance, transitioning from profit to a net loss of 77.9026 million yuan in 2024, primarily due to weakened downstream market demand and intense competition [1][2]. Financial Performance - In 2024, Kangtai Medical achieved an operating revenue of 480 million yuan, representing a year-on-year decrease of 35.76% [2]. - The company has experienced a continuous decline in net profit for four consecutive years since 2021 [1]. Shareholder Actions - The actual controller of Kangtai Medical, Hu Kun, announced a plan to reduce his shareholding by up to 12 million shares, which is approximately 2.9865% of the total share capital, due to personal financial needs [1][2]. Business Operations - Kangtai Medical specializes in the research, production, and sales of medical diagnostic and monitoring equipment, with a product range that includes blood oxygen, electrocardiogram, ultrasound, monitoring, blood pressure, and analytical testing devices [2]. - The company has developed three main product systems: hospital-based, home-based, and others, serving various healthcare settings [2]. Challenges Faced - The company cited several challenges impacting its business, including increased competition in the global medical device market, stricter regulatory requirements, and reduced procurement budgets from governments and medical institutions [2][3]. - The decline in sales volume and prices of major products has led to a significant drop in main business income [3]. Inventory and R&D Expenses - Kangtai Medical reported a high balance of raw materials and semi-finished goods due to previous market conditions, leading to a slowdown in inventory turnover and a need to recognize a substantial inventory impairment provision of 109 million yuan [3]. - The company maintained a high level of R&D investment, with expenses amounting to 105 million yuan in 2024, which has also impacted net profit in the short term [3].